In order to further elucidate whether the effect of KIFC3 on CRC cells is related to PI3K/AKT/mTOR pathway, LY294002 (an inhibitor of PI3K/AKT/mTOR pathway) and Triciribine (an inhibitor of AKT) was used to treat KIFC3-overexpressing cells individually. The gene discussed is MTOR; the disease is colorectal carcinoma.